- Home
- VCYT vs APLS Comparison
VCYT vs APLS Comparison
Compare VCYT & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCYT
- APLS
- Stock Information
- Founded
- VCYT 2006
- APLS 2009
- Country
- VCYT United States
- APLS United States
- Employees
- VCYT N/A
- APLS N/A
- Industry
- VCYT Medical Specialities
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- VCYT Health Care
- APLS Health Care
- Exchange
- VCYT Nasdaq
- APLS Nasdaq
- Market Cap
- VCYT 2.9B
- APLS 2.9B
- IPO Year
- VCYT 2013
- APLS 2017
- Fundamental
- Price
- VCYT $41.51
- APLS $19.29
- Analyst Decision
- VCYT Buy
- APLS Buy
- Analyst Count
- VCYT 10
- APLS 19
- Target Price
- VCYT $42.40
- APLS $32.83
- AVG Volume (30 Days)
- VCYT 1.0M
- APLS 3.2M
- Earning Date
- VCYT 11-04-2025
- APLS 10-30-2025
- Dividend Yield
- VCYT N/A
- APLS N/A
- EPS Growth
- VCYT N/A
- APLS N/A
- EPS
- VCYT 0.38
- APLS 0.36
- Revenue
- VCYT $495,141,000.00
- APLS $1,016,397,000.00
- Revenue This Year
- VCYT $14.52
- APLS $25.39
- Revenue Next Year
- VCYT $9.90
- APLS N/A
- P/E Ratio
- VCYT $109.62
- APLS $53.78
- Revenue Growth
- VCYT 16.41
- APLS 42.11
- 52 Week Low
- VCYT $22.61
- APLS $16.10
- 52 Week High
- VCYT $47.32
- APLS $35.72
- Technical
- Relative Strength Index (RSI)
- VCYT 63.38
- APLS 32.42
- Support Level
- VCYT $35.27
- APLS $19.44
- Resistance Level
- VCYT $46.41
- APLS $30.48
- Average True Range (ATR)
- VCYT 1.92
- APLS 1.43
- MACD
- VCYT 0.62
- APLS -0.95
- Stochastic Oscillator
- VCYT 59.02
- APLS 4.52
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.